Johnson & Johnson (JNJ) Stock Forecast & Price Target

$162.19

+0.13 (+0.08%)

(As of 11:23 AM ET)

Johnson & Johnson - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 13 Analyst Ratings

Sell
0

Hold
7

Buy
6

Based on 13 Wall Street analysts who have issued ratings for Johnson & Johnson in the last 12 months, the stock has a consensus rating of "Hold." Out of the 13 analysts, 7 have given a hold rating, and 6 have given a buy rating for JNJ.

Consensus Price Target

$173.21
6.91% Upside

According to the 13 analysts' twelve-month price targets for Johnson & Johnson, the average price target is $173.21. The highest price target for JNJ is $215.00, while the lowest price target for JNJ is $150.00. The average price target represents a forecasted upside of 6.91% from the current price of $162.19.

Get the Latest News and Ratings for JNJ and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Johnson & Johnson and its competitors.

JNJ Analyst Ratings Over Time

Type	Current Forecast 10/2/23 to 10/1/24	1 Month Ago 9/2/23 to 9/1/24	3 Months Ago 7/4/23 to 7/3/24	1 Year Ago 10/2/22 to 10/2/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)
Hold	7 Hold rating(s)	7 Hold rating(s)	8 Hold rating(s)	9 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$173.21	$173.21	$174.07	$170.65
Forecasted Upside	6.91% Upside	4.43% Upside	19.54% Upside	10.01% Upside
Consensus Rating	Hold	Hold	Hold	Hold

The world’s smartest man is in their crosshairs (Ad)

Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump.

Watch this new documentary and you’ll discover what Elon knows,

JNJ Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

JNJ Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Johnson & Johnson Stock vs. The Competition

Type	Johnson & Johnson	Medical Companies	S&P 500
Consensus Rating Score	2.46	2.78	2.50
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	6.91% Upside	823.00% Upside	6.15% Upside
News Sentiment Rating	Neutral News See Recent JNJ News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/30/2024	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$215.00 ➝ $215.00	+33.21%
9/20/2024	Royal Bank of Canada 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$175.00 ➝ $175.00	+6.82%
7/23/2024	Daiwa America 0 of 5 stars	N. Nakagiri Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/23/2024	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$160.00 ➝ $150.00	-2.75%
7/19/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$160.00 ➝ $155.00	+0.27%
7/18/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$161.00 ➝ $171.00	+9.10%
Get the Latest News and Ratings for JNJ and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter.
7/18/2024	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$195.00 ➝ $185.00	+18.03%
7/18/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$195.00 ➝ $185.00	+18.38%
7/18/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$167.00 ➝ $169.00	+7.93%
4/18/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$169.00 ➝ $170.00	+17.43%
4/17/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$180.00 ➝ $170.00	+17.96%
1/3/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$172.00 ➝ $175.00	+8.93%
12/13/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight	$170.00 ➝ $163.00	+5.11%
12/1/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$167.00 ➝ $180.00	+16.39%
10/12/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$158.00 ➝ $162.00	+3.73%
8/4/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$167.00 ➝ $170.00	-0.42%
7/21/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral	$175.00 ➝ $180.00	+5.75%
7/21/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$165.00 ➝ $175.00	+3.92%
7/21/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral	$170.00 ➝ $175.00	+3.92%
5/30/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$185.00	+19.86%
2/28/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$161.00	+5.05%
2/6/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$55.00 ➝ $52.00	-68.17%
1/20/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$194.00 ➝ $186.00	+9.72%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 11:27 AM ET.

Should I Buy Johnson & Johnson Stock? JNJ Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, September 29, 2024. Please send any questions or comments about these Johnson & Johnson pros and cons to contact@marketbeat.com.

Johnson & Johnson
Bull Case

Here are some ways that investors could benefit from investing in Johnson & Johnson:

Johnson & Johnson's stock price has shown stability and growth potential, with a current price of $163.21.
Johnson & Johnson consistently beats analysts' earnings per share estimates, indicating strong financial performance.
Johnson & Johnson has a solid dividend yield of 2.97%, providing investors with a steady income stream.
Institutional investors, such as Norges Bank and Wellington Management Group LLP, have made significant investments in Johnson & Johnson, reflecting confidence in the company.
Johnson & Johnson's diverse product portfolio in the healthcare sector offers resilience and potential for long-term growth.

Johnson & Johnson
Bear Case

Investors should be bearish about investing in Johnson & Johnson for these reasons:

Johnson & Johnson faces regulatory challenges and litigation risks in the healthcare industry, which could impact its financial performance.
The company's debt-to-equity ratio of 0.44 may raise concerns about its leverage and financial stability.
Competition in the healthcare sector is intense, leading to pricing pressures and potential market share erosion for Johnson & Johnson.
Johnson & Johnson's P/E ratio of 10.18 and P/E/G ratio of 2.71 may indicate that the stock is currently overvalued.
Economic uncertainties and global health trends could affect demand for Johnson & Johnson's products and services.

JNJ Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Johnson & Johnson is $173.21, with a high forecast of $215.00 and a low forecast of $150.00.
: 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" JNJ shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in JNJ, but not buy additional shares or sell existing shares.
: According to analysts, Johnson & Johnson's stock has a predicted upside of 6.80% based on their 12-month stock forecasts.
: Over the previous 90 days, Johnson & Johnson's stock had 2 downgrades by analysts.
: Johnson & Johnson has been rated by research analysts at Cantor Fitzgerald, Daiwa America, Daiwa Capital Markets, Morgan Stanley, Royal Bank of Canada, Sanford C. Bernstein, TD Cowen, TD Securities, and The Goldman Sachs Group in the past 90 days.
: Analysts like Johnson & Johnson less than other "medical" companies. The consensus rating for Johnson & Johnson is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how JNJ compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Solar Energy: What Donald Trump, Elon Musk, and the DNC All Agree On (Ad)

Find out how one NASDAQ-listed company is poised to tackle the home energy crisis, bringing a unique solution to soaring costs - one that's already being delivered to thousands of homes across North America... And sought after by some of the world's most valuable companies, including Fortune 100-listed Honeywell International.

GET THE FULL REPORT NOW

This page (NYSE:JNJ) was last updated on 10/1/2024 by MarketBeat.com Staff

From Our Partners